Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovaBay Pharmaceuticals (NBY) Amortization of Deferred Charges (2019 - 2020)

Historic Amortization of Deferred Charges for NovaBay Pharmaceuticals (NBY) over the last 2 years, with Q3 2020 value amounting to -$2000.0.

  • NovaBay Pharmaceuticals' Amortization of Deferred Charges fell 10085.11% to -$2000.0 in Q3 2020 from the same period last year, while for Dec 2021 it was -$2000.0, marking a year-over-year decrease of 10141.84%. This contributed to the annual value of $141000.0 for FY2020, which is 7895.52% down from last year.
  • Per NovaBay Pharmaceuticals' latest filing, its Amortization of Deferred Charges stood at -$2000.0 for Q3 2020, which was down 10085.11% from $38000.0 recorded in Q2 2020.
  • In the past 5 years, NovaBay Pharmaceuticals' Amortization of Deferred Charges ranged from a high of $243000.0 in Q2 2019 and a low of -$2000.0 during Q3 2020